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Interleukin 23 (IL-23) is an inflammatory cytokine that plays 
an important role in tumor promotion. Expression of IL-23 
is increased in cancer cells and correlates with tumor pro-
gression. However, the mechanisms regulating IL-23 
expression in cancer cells are still unclear. Here we report 
that tristetraprolin (TTP), an AU-rich element (ARE)-binding 
protein, inhibits IL-23 production in CT26 mouse colon 
cancer cells. Overexpression of TTP decreased the stabili-
ty of IL-23 mRNA and the expression level of IL-23 in CT26 
cells. Conversely, inhibition of TTP by siRNA increased IL-
23 production. TTP destabilized a luciferase mRNA report-
er containing the IL-23 mRNA 3’UTR, which contains five 
AREs. Analyses of deletion and point mutants of the IL-23 
mRNA 3’UTR demonstrated that the ARE cluster between 
the third and fifth AREs was responsible for TTP-mediated 
destabilization of IL-23 mRNA. A RNA electrophoretic mo-
bility shift assay confirmed that TTP binds to this ARE 
cluster. Taken together, these results demonstrate that 
TTP acts as a negative regulator of IL-23 gene expression 
in mouse colon cancer cells and suggest its potential ap-
plication as a novel therapeutic target to control IL-23-





IL-23 is an important pro-inflammatory heterodimeric cytokine 
formed by linkage of p40 and p19 subunits that acts as a cru-
cial regulator to drive a pathway that leads to the generation of 
IL-17–producing CD4 T cells (Aggarwal et al., 2003; Cua et al., 
2003; Harrington et al., 2005; Langrish et al., 2004). The induc-
tion of IL-23–mediated processes leads to recruitment of a 
range of inflammatory cells in addition to T helper 17 cells, and 
has been shown to be crucial to the pathogenesis of a number 
of immune-mediated inflammatory diseases (Langrish et al., 
2005). In a recent study, IL-23 emerged as a new player in the 
promotion of tumor growth and development through suppres-
sion of tumor infiltration of CD8+ T cells and promotion of tumor 
angiogenesis and metastases (Langowski et al., 2006; Teng et 
al., 2010). Moreover, anti-IL-23 monoclonal antibody acts syn-
ergistically with targeted therapies or IL-2 to suppress tumor 
growth and metastases (Teng et al., 2011), supporting the tu-
mor-promoting activity of IL-23.  
Many inflammatory cytokine and chemokine mRNAs are 
known to be unstable (Anderson, 2008). Expression of these 
mRNAs is modulated by post-transcriptional control, which is 
strongly dependent on AU-rich element (ARE)-mediated me-
chanisms (Stoecklin and Anderson, 2006). The AREs may 
destabilize inflammatory signaling mRNAs through specific 
binding of proteins that promote mRNA degradation (Caput et 
al., 1986; Shyu and Wilkinson 2000). Tristetraprolin (TTP) is a 
well-characterized ARE-binding protein that is involved in post-
transcriptional regulation of inflammatory cytokines, proto-onco-
genes, and growth regulatory genes (Cha et al., 2011; Lee et 
al., 2010a; 2011; 2012; 2013). TTP-knockout mice develop 
severe inflammatory arthritis and autoimmune dysfunction, 
indicating a role of TTP in limiting the inflammatory response 
(Taylor et al., 1996).  
Macrophages and DCs are known to be the predominant 
producers of IL-23 (Hunter, 2005). The 3’UTR of IL-23 p19 
mRNA contains multiple AREs and IL-23 p19 expression in 
macrophages is suppressed by TTP-mediated degradation of 
p19 mRNA (Qian et al., 2011). Recently, it has been reported 
that IL-23 is highly expressed in many tumors, including breast, 
prostate, liver, and skin cancers and head and neck squamous 
cell carcinoma (HNSCC), and that levels of IL-23 correlate with 
tumor progression (Kesselring et al., 2010; Langowski et al., 
2006; Martin-Orozco et al., 2009). However, there are no con-
vincing studies demonstrating the molecular basis for the regu-
lation of IL-23 in cancer cells.  
In the present study, we provide evidence that TTP inhibits 
IL-23 expression by enhancing the decay of IL-23 p19 mRNA in 
cancer cells. IL-23 transcript was detected in CT26 colon can-
cer cells. Overexpression of TTP decreased IL-23 expression 
level whereas inhibition of TTP by siRNA increased it. IL-23 
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binding of TTP to these AREs enhances decay of the mRNA. 
These results support a procarcinogenic role for IL-23 and sug-
gest that TTP-mediated inhibition of IL-23 expression in cancer 
cells might provide a novel therapeutic strategy for the sup-
pression of tumor-promoting inflammation.  
 
MATERIALS AND METHODS 
 
Cells 
The CT26 and 293 EBNA cell lines were purchased from the 
American Type Culture Collection (USA) and maintained in 
RPMI 1640 media supplemented with 10% FBS (HyClone) at 
37°C in a humidified atmosphere of 5% CO2. 
 
Plasmids and siRNAs  
The pcDNA6/V5-TTP construct has been described previously 
(Lee et al., 2010b). Mouse IL-23 p19 3′UTR was PCR amplified 
from cDNA of CT26 cells using Taq polymerase (SunGenetics, 
Korea) and the primers CCGCTCGAGGAGCTCTGGGGA 
GCCCACACT and ATAAGAATGCGGCCGCGGGCGAAAAT 
GGTTACGATGTG (underlined letters indicate restriction sites). 
PCR products were inserted into the XhoI/NotI sites of a psi-
CHECK2 Renilla/firefly dual-luciferase expression vector (Pro-
mega, USA) to generate the construct psiCHECK2/IL-23 
3′UTR Full. The psiCHECK2/IL-23 3′UTR Full construct was 
used as a template to synthesize the deletion mutant construct 
psiCHECK2/IL-23 Frag-ΔARE. PCR primers used for mutant 
constructs were TAAGGGCTTTAAGTTATATGCCCTGAGAT 
AACT and AGTTATCTCAGGGCATATAACTTAAAGCCCTTA.  
An oligonucleotide containing the five AUUUA motifs (ARE-1-
5) of the IL-23 p19 mRNA 3′UTR was synthesized at Integrated 
DNA Technologies (USA) (Table 1). Mutant oligonucleotides in 
which single (ARE-M-1, ARE-M-2, ARE-M-3, ARE-M-4, or ARE- 
M-5) or all five AUUUA pentamers (ARE-M all) were sub-stitu-
ted with AGCA were also synthesized. The oligonucleotides 
were ligated into the XhoI/NotI site of the psiCHECK2 vector.  
Small interfering RNAs (siRNAs) against mouse TTP (TTP-
siRNA; sc-36760) and control siRNA (scRNA; sc-37007) were 
purchased from Santa Cruz Biotechnology (USA). 
 
Transfections and luciferase assay 
Cells (5 × 106) were electroporated with various plasmid con-
structs and siRNAs at 1,400 V and 30 ms using the Neon™ 
Transfection System (Invitrogen, USA) according to the manu-
facturer’s instructions. 
Lysates of transfected cells were mixed with luciferase assay 
reagent (Promega, USA) and the chemiluminescent signal was 
measured in a Wallac Victor 1420 Multilabel Counter (EG&G 
Wallac, Finland). Renilla luciferase activity of psiCHECK2/ IL-23 
3′UTR Full was normalized to firefly luciferase for each sample.  
 
Electrophoretic mobility shift assay (EMSA)  
The biotinylated RNA probes for wild-type ARE (Oligo-ARE-3/4, 
5′-CCUGUAUUUAUUUGAGCUAUUUAAGGAUCUAUUUAUG 
UUUAAGUAUUUAGAAAA-3′) and mutant ARE (Oligo-ARE-
m3/4, 5′-CCUGUAGCAUUUGAGCUAGCAAGGAUCUAGCAU 
GUUUAAGUAGCAGAAAA-3′) were synthesized by Samchully 
Pharm. Co., LTD (Korea). A mutant RNA probe in which the 
AUUUA pentamers were all substituted with AGCA was used 
as a negative control. Cytoplasmic extracts were prepared from 
CT26 cells using NE-PER® Nuclear and Cytoplasmic extraction 
Reagent (Thermo Pierce Biotechnology Scientific, USA). RNA 
EMSA was performed using the Lightshift® Chemoluminescent 
EMSA Kit (Thermo Pierce Biotechnology Scientific) according 
to the manufacturer’s instructions. Briefly, 20 fmol of biotiny-
lated RNA was combined with 4 μg of cytoplasmic cellular pro-
tein in a binding buffer. For the supershift EMSA, anti-TTP anti-
body (ab36558, Abcam, USA) or control antibody (I-5381, Sig-
ma) was added to the reaction mixture. After the addition of 
antibodies, reaction mixtures were incubated overnight on ice. 
The reaction products were resolved on 5% nondenaturing 
polyacrylamide gels in 0.5× Tris borate/EDTA buffer. Gels were 
transferred to nylon membrane (Hybond™-N+) in 0.5× Tris bo-
rate/EDTA at 100 V and 4°C for 1 h. The RNAs were cross-
linked to the membrane and detected using streptavidin-
horseradish peroxidase binding and chemiluminescence. 
 
SDS-PAGE analysis and immunoblotting 
Proteins were resolved by SDS-PAGE, transferred to Hybond-
P membranes (GE Healthcare Bio-Sciences Corp., USA), and 
probed with the appropriate dilution of anti-TTP antibody 
(ab36558, Abcam) and anti-V5 antibody (20-783-70389, Gen-
Way). Immunoreactivity was detected using the ECL detection 
system (GE Healthcare Bio-Sciences Corp.). Films were ex-
posed at multiple time points to ensure that images were not 
saturated. 
 
Quantitative real-time PCR 
For kinetic analysis of mRNA expression, we used actinomycin 
D to inhibit transcription and assessed IL-23 p19 mRNA ex-
pression by quantitative real-time PCR (qRT-PCR). qRT-PCR 
was performed by monitoring the increase in fluorescence of 
the SYBR Green dye (QIAGEN, Germany) in real-time using 
ABI Prism 7900 HT. Specificity of each primer pair was con-
firmed by melting curve analysis and agarose gel electrophore-
sis. PCR primer pairs were as follows: qIL-23: ACTACAACCG 
ATCCACCTCAC and ACTTTGCCTCCCAGATCACAG; qGAPDH: 




For statistical comparisons, p values were determined using 




TTP regulates the expression level of IL-23 
Chronic inflammation is thought to be the leading cause of 
many human cancers including colon cancer (Terzic et al., 
2010). The proinflammatory cytokine IL-23 has emerged as a 
new player in the promotion of tumor growth and development. 
It was recently reported that IL-23 expression is highly ex-
pressed in many tumors and that the level of IL-23 correlates 
with tumor progression. Here, we investigated whether TTP 
regulates the expression of IL-23 in CT26 colon cancer cells. 
To determine the effect of TTP on IL-23 expression, the TTP 
expression vector pcDNA6/V5-TTP or pcDNA6/V6 as a vector 
control was transfected into CT26 cells. Overexpression of TTP 
was confirmed by RT-PCR and Western blot analyses. The 
expression of IL-23 was significantly reduced in pcDNA6/V5-
TTP-transfected cells compared with cells transfected with 
empty vector (Figs. 1A and 1B).  
Next, we determined whether specific inhibition of TTP by 
siRNA affected IL-23 expression in CT26 cells. Down-regula-
tion of TTP by treatment with siRNA-TTP significantly increased 
the expression level of IL-23 (Figs. 1C and 1D). However, 
treatment with a non-specific siRNA (scRNA) did not decrease 
the expression level of endogenous TTP or induce a change in
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IL-23 expression. Collectively, these results indicate that the 
expression of IL-23 is regulated by changes in TTP expression 
in the CT26 mouse colon cancer cell line. 
 
Overexpression of TTP decreases the expression level of  
luciferase mRNA containing the IL-23 3′UTR 
TTP protein regulates mRNA stability through binding to AREs 
within the mRNA 3′UTR. Analysis of the 655-bp human IL-23 
3′UTR revealed the presence of five pentameric AUUUA motifs 
(Fig. 2A). To determine whether the TTP inhibitory effect is 
mediated through the IL-23 mRNA 3′UTR we prepared three 
IL-23 mRNA 3′UTR fragments: full length (containing full-length 
IL-23 mRNA 3′UTR), ΔARE (containing none of the pentameric 
AUUUA motifs, and ARE1-5 (containing all five motifs). To 
assay promoter activity we used a luciferase reporter gene 
linked to these fragments in the plasmid psiCHECK. First, we 
confirmed that transfection of 293 EBNA and CT26 cells with 
the human and mouse pcDNA6/TTP vector significantly sup-
pressed the luciferase activity of a reporter gene containing full-
length IL-23 mRNA 3’UTR (approximately 80% inhibition) com-
pared with cells transfected with the empty vector pcDNA6/V5 
(Figs. 2B and 2C). Although overexpression of TTP did not 
affect the luciferase activity of a reporter gene containing ΔARE 
(13% inhibition), it significantly inhibited activity of the ARE1-5 
construct (85% inhibition) (Fig. 2D). These results demonstrat-
ed that the ARE1-5 region containing five AUUUA pentamers is 
important for TTP-mediated down-regulation of IL-23 expres-
sion. 
To determine which AUUUA pentamer(s) is essential for the 
inhibitory effect of TTP, we prepared luciferase reporter genes 
containing wild-type or mutant oligonucleotides as follows: Oli-
go ARE 1-5 (containing wild-type AREs 1-5); Oligo ARE-AM 
(containing mutant AREs 1-5); Oligo ARE-M1 (containing mu-
tant ARE 1 and wild-type ARE 2-5); Oligo ARE M2 (mutant 
ARE 2); Oligo ARE M3 (mutant ARE 3); Oligo ARE M4 (mutant 
ARE 4); Oligo ARE M5 (mutant ARE 5). As expected, Oligo 
ARE 1-5 MUT did not respond to TTP (23% inhibition) whereas 
TTP significantly inhibited activity of the ARE1-5 construct (85% 
inhibition). Any single mutation among the five ARE motifs atte-
nuated the TTP inhibitory effect (34-60% inhibition). In particular, 
mutations ARE 3, 4, and 5 had a stronger effect than ARE 1 
and ARE 2, indicating that the cluster of ARE 3-5 is required for 
efficient TTP inhibitory function (Fig. 2D).  
 
TTP destabilizes IL-23 mRNA 
To determine whether the decreased expression of IL-23 re-
sulted from changes in the stability of IL-23 mRNA, we meas-
ured the half-life of IL-23 mRNA by quantitative real-time PCR 
in actinomycin D-treated CT26 cells transfected with vector 
carrying TTP (CT26/TTP) or empty vector (CT26/pcDNA). In 
CT26/pcDNA cells, IL-23 mRNA was stable until 1 h after acti-
nomycin D treatment. However, in CT26/TTP cells the half-life 
of IL-23 mRNA was 45 min (Fig. 3A), indicating that increased 
expression of TTP contributes to a decrease in IL-23 levels 
through destabilization of IL-23 mRNA.  
 
TTP binds to the ARE cluster within the IL-23 mRNA 3′UTR 
To determine the interaction of TTP with the ARE cluster of IL-
23-3′UTR, RNA EMSA was conducted using a biotinylated 
RNA probe containing the wild type or mutant ARE cluster of 
the IL-23 mRNA 3′UTR. Cytoplasmic extracts were prepared 
from CT26 cells transfected with pcDNA6/V5-TTP and incu-
bated with the biotinylated RNA probes. When RNA EMSA was 
conducted using the wild type IL-23 probe, a dominant probe-
protein complex was observed (Fig 3B). However, mutation of 
the IL-23 ARE prevented formation of this complex. The amount 
of this RNA-protein complex was reduced by preincubation with 
TTP-antibody in the reaction mixture in a concentration-depen-
Fig. 1. TTP inhibits IL-23 expression in CT26 mouse
colorectal cancer cells. CT26 cells were transfected with
pcDNA6/V5-TTP or pcDNA6/V5 (A, B), and with TTP-
siRNA (siTTP) or control-siRNA (scRNA) (C, D). Ex-
pression of TTP and IL-23 in cells was determined by (A)
semiquantitative real-time PCR (top panel) and Western
blot analysis (bottom panel), or (B, C, and D) quantitative
real-time PCR. GAPDH and β-actin were included as
loading controls for PCR and Western blot analysis,
respectively. Results shown represent the mean ± SD of
three independent experiments (**P < 0.01; ***P <
0.001). 
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in the IL-23 mRNA 3′UTR that is required for TTP inhibition of luciferase activity. CT26 cells were cotransfected with 0.5 μg of a luciferase 
reporter construct as described in (A) and either pcDNA6/V5-TTP or the empty vector pcDNA6/V5. After normalization of luciferase activity, the 
TTP-induced inhibition of luciferase activity observed with each construct was compared with inhibition obtained with the full-length IL-23 























dent manner. There was no change in the complex when the 
mixture was preincubated with an anti-IgG as a negative control. 
These results showed that TTP directly interacts with the ARE 




IL-23 is highly expressed in many tumors and the levels of IL-
23 correlate with tumor progression (Kesselring et al., 2010; 
Langowski et al., 2006; Martin-Orozco et al., 2009). However, 
the molecular basis for the regulation of IL-23 in cancer cells is 
not fully understood. In this study, we provide evidence that 
TTP suppresses IL-23 expression by binding to the 3′UTR of 
IL-23 mRNA and promoting IL-23 mRNA degradation in cancer 
cells. TTP overexpression decreased the expression of a lucife-
rase reporter gene containing the IL-23 mRNA 3′UTR and de-
creased IL-23 expression level whereas inhibition of TTP by 
siRNA increased IL-23 expression level.  
Macrophages and DCs are the predominant producers of IL-
23 (Hunter, 2005). In macrophages, IL-23 p19 expression has 
been reported to be suppressed by TTP-mediated degradation 
of p19 mRNA, and ARE clusters in the IL-23 3′UTR have been 
shown to participate in the regulation of mRNA stability (Qian et 
al., 2011). Consistent with this result, we found that TTP pro-
moted IL-23 mRNA degradation through binding to a cluster of 
five ARE motifs within the IL-23 mRNA 3′UTR. Moreover, dele-
tion and mutation analysis showed that these five AREs are 
required for efficient response to TTP in cancer cells. However, 
we found that the five AREs did not respond equally to TTP 
and that the cluster of the third to fifth AREs was primarily re-
Fig. 2. AREs within the IL-23 mRNA 3′UTR are 
essential for the inhibitory effect of TTP. (A) 
Schematic representation of the luciferase report-
er constructs used in this study. Fragments and 
oligonucleotides derived from the IL-23 mRNA 
3′UTR were cloned upstream of the luciferase 
reporter gene in the psiCHECK2 luciferase ex-
pression vector. White circles represent the wild-
type (w) pentameric motif, AUUUA, and black 
circles represent the mutated (m) motif, AGCA. 
(B, C) TTP overexpression inhibited activity of the 
luciferase reporter containing the IL-23 3′UTR. (B, 
C) 293 EBNA (B) and CT26 (C) cells were co-
transfected with luciferase reporters containing 
full-length IL-23 mRNA 3′UTR (IL-23 3′UTR Full) 
and with either pcDNA/V5-TTP or the empty 
pcDNA/V5 control vector. Cells were harvested 
and Renilla luciferase activity was normalized to 
firefly activity. The luciferase values obtained from 
cells cotransfected with the luciferase construct 
and pcDNA6/V5 were set to 1. Results shown 
represent the mean ± SD of three independent 
experiments (p < 0.05). (D) Mapping of the region 
 
Fig. 3. (A) TTP destabilizes IL-23 mRNA. CT26 cells
were transfected with pcDNA6/V5-TTP or pcDNA6/
V5. Expression of IL-23 mRNA in CT26 cells was
determined by quantitative real-time PCR at the
indicated times after addition of 5 μg/ml actinomycin
D. Data shown represent mean ± SD of three inde-
pendent experiments. (**P < 0.01) (B) TTP binds to
the ARE cluster within the IL-23 mRNA 3′UTR. An
RNA EMSA was performed by mixing cytoplasmic
extracts containing 4 μg of total protein from CT26
cells with 10 fmol of biotinylated wild-type or mutant
probe. Anti-TTP or control antibody was added to the
reaction mixtures. The binding reaction products
were separated by electrophoresis on a 5% polya-
crylamide gel under non-denaturing conditions. Ar-
rows indicate the position of the TTP-containing band.
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sponsible for TTP inhibitory function. It has been reported that 
TTP-mediated mRNA decay requires the recruitment of ex-
onucleases such as Dcp2 and Xrn1 (Lykke-Andersen and 
Wagner, 2005). We have previously reported that binding of 
TTP to the ARE motif is not sufficient for the recruitment of 
Dcp2 and Xrn1, but additional sequences surrounding the ARE 
motif are important for recruiting exonucleases and inducing 
TTP-mediated mRNA decay (Kim et al., 2010). The nucleotide 
sequences responsible for exonuclease recruitment have not 
yet been determined and we did not compare the nucleotide 
sequences surrounding the five AREs within the IL-23 mRNA 
3′UTR. It is possible that the nucleotide sequences surrounding 
the first and second AREs may not suitable for recruitment of 
Dcp2 and Xrn1. Further studies on the nucleotide sequences 
surrounding the AREs and the recruitment of exonucleases to 
each AREs are necessary to understand the basic mechan-
isms.  
TTP is one of the best-characterized proteins among the 
ARE-binding proteins that promote degradation of ARE-con-
taining transcripts (Carballo et al., 1998; Lykke-Andersen and 
Wagner, 2005). TTP expression is significantly decreased in 
various cancers (Brennan et al., 2009), and this down-regula-
tion correlates with increased expression of proto-oncogenes 
(Lee et al., 2010a; Young et al., 2009). The low level of TTP in 
cancer cells may not be sufficient to inhibit IL-23 expression, 
resulting in high IL-23 levels in cancer cells (Kesselring et al., 
2010; Langowski et al., 2006; Martin-Orozco et al., 2009) which 
in turn may support tumor development. In this study, we pro-
vide evidence that ectopic expression of TTP decreased the IL-
23 level in cancer cells. It has been reported that stimulation 
with LPS results in a strong and rapid induction of TTP mRNA 
in mouse macrophages (Mahtani et al., 2001). However, LPS 
stimulation does not enhance the TTP-mediated degradation of 
ARE-containing mRNA because it also activates p38 MAPK, 
which can phosphorylate and inactivate TTP (Chrestensen et 
al., 2004; Stoecklin et al., 2004). Stimulation with IFN-γ (Sauer 
et al., 2006), IL-10 (Schaljo et al., 2009) or nicotine (Joe et al., 
2011) has been reported to induce TTP expression but not p38 
MAPK activity and thus these agents increase the induction of 
mRNA decay by TTP. IFN-γ has been reported to increase 
both the level and the activity of TTP and enhance the TTP-
mediated degradation of IL-23 mRNA in macrophages (Qian et 
al., 2011). The effects of these factors on TTP level and activity 
have been reported mostly in macrophages and it is not clear 
whether these factors are also involved in the induction of TTP 
in cancer cells. Even though TGF-β does not induce TTP ex-
pression, it can increase TTP activity by inhibition of p38 MAPK 
activity in cancer cells (Lee et al., 2011). Further studies are 
needed to determine whether these factors increase TTP ex-
pression and/or activity and lead to inhibition of IL-23 expres-
sion in cancer cells.  
In conclusion, we demonstrate that TTP inhibits IL-23 pro-
duction in cancer cells by promoting IL-23 mRNA degradation. 
Because IL-23 promotes tumor growth and metastasis, the 
inhibition of IL-23 production through enhanced TTP expres-
sion and activity may have important clinical implications.  
 
Note: Supplementary information is available on the Molecules 
and Cells website (www.molcells.org). 
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